HemaCare Corporation, a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular process development, has released operational highlights and financial results for the six months ended June 30, 2019, which included investment in the company’s Donor Center and Biorepository. Product and services revenue growth was primarily due to customized cell isolation, processing and cryopreservation, specialized collection of leukopaks and mobilized peripheral blood.
HemaCare was founded in 1978 and is headquartered in the Greater Los Angeles Area. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution.
HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.
Select operational highlights include:
In January, at the Phacilitate Cell & Gene Therapy World Conference, HemaCare partnered with Hitachi Chemical Advanced Therapeutics Solutions (HCATS) on a presentation titled, “Improved Stability and Quality of Donor Starting Material.” This was followed up in February with a joint webinar hosted with HCATS titled, “Managing Starting Material Stability to Maximize Manufacturing Flexibility & Downstream Efficiency.”
In February, HemaCare executed a strategic collaboration with a long-time global distributor, Tissue Solutions. This strategic collaboration expands the disease state product portfolio for HemaCare clients and leverages Tissue Solutions’ expertise in sourcing these critical materials.
In May, HemaCare executed a distributor agreement with FujiFilm (Wako Pure Chemical Corporation) for distribution of its cryopreserved products in Japan. This agreement will further drive growth in this rapidly expanding research market.
In July, HemaCare announced a branding initiative around HemaPrime™ (research use) and GMPrime™ (GMP-compliant) cells and tissues, providing clients with access to the premium quality materials needed to support research from bench to commercialization.
“We continue to strengthen our position as the trusted brand and global leader in the production and customization of the highest quality human-derived cellular products for research, drug discovery, development and commercial production of cell and gene therapies.”
“HemaCare is committed to the highest levels of quality and regulatory compliance in the industry. We maintain rigorous ongoing training programs for our team, and comprehensive validation programs of our facility, equipment, and processes to ensure customers receive consistent, high-quality products and services. Our quality system is based on strict regulatory requirements and industry best practices.” – Pete van der Wal, President and Chief Executive, HemaCare
Sources
- https://www.businesswire.com/news/home/20190820005229/en/HemaCare-Reports-2019-Results
- https://www.crunchbase.com/organization/hemacare
